Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 1.00 |
| ▸ | BCR | P11274 | 18/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395506 | 0.80 | ABL1 (0.67) | ABL1BCR | |
| SCHEMBL3399556 | 0.76 | ABL1 (0.78) | ABL1BCR | |
| SCHEMBL3399551 | 0.76 | ABL1 (0.61) | ABL1BCR | |
| SCHEMBL12942539 | 0.75 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL16609188 | 0.75 | ABL1 (0.60) | ABL1BCR | |
| SCHEMBL3915342 | 0.74 | ABL1 (1.00) | ABL1BCR | |
| SCHEMBL925183 | 0.74 | ABL1 (0.62) | ABL1BCR | |
| SCHEMBL30559792 | 0.73 | ABL1 (0.57) | ABL1BCRCCNT1CCNE1CDK2 | |
| SCHEMBL21570550 | 0.73 | ABL1 (0.57) | ABL1BCRCCNT1CCNE1CDK2 | |
| SCHEMBL26429094 | 0.73 | ABL1 (0.60) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021524-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2011-01-27 | — | — | US | disclosed |
| WO-2009091476-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2009-07-23 | — | — | WO | disclosed |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021524-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | ABL1, BCR, MCL1 | ABL1 1/4885BCR 2/4885CCNT1 2223/4885 |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | ABL1, BCR, PDGFRA | ABL1 1/4885BCR 2/4885CCNT1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.